CARDIOLOGY I BREAKOUT SESSIONS. May Lisbon PORTUGAL Hotel da Estrela. Atrial Fibrillation/ Venous TromboEmbolism

Transcription

1 BREAKOUT SESSIONS CARDIOLOGY I Atrial Fibrillation/ Venous TromboEmbolism Advanced Clinical Knowledge for Pharmacists

2 OUR EXPERTS Helen Williams MRPharmS PGDip(Cardiol) Ipresc \ Consultant Pharmacist for Cardiovascular Disease for South London Cardiac and Stroke Networks and Southwark Health and Social Care Network. Sotiris Antoniou FFRPS MRPharmS MSc Dip Mgt IPresc \ Consultant Pharmacist, Cardiovascular Medicine, Barts Health NHS Trust.

3 WE WILL DISCUSS ABOUT CARDIOLOGY I Atrial Fibrillation/ Venous TromboEmbolism Atrial Fibrillation \ Understand the pathophysiology of atrial fibrillation and explain the importance of atrial fibrillation as a risk factor for stroke Venous Thromboembolism \ Understand the pathophysiology of venous thromboembolism and the implications of VTE for healthcare systems \ Discuss the key recommendations relating to AF -related stroke prevention in national and international guidelines \ Discuss the key recommendations relating to the treatment and prevention of VTE in national and international guidelines \ Apply the evidence base supporting the different pharmacological agents available to reduce stroke risk in Atrial Fibrillation to the care of individual patients \ Explain the benefits and risks of anticoagulation for stroke prevention in AF to : \ Other clinicians \ Patients \ Apply the evidence base supporting the different pharmacological agents available to treat VTE to the care of individual patients \ Understand the principles of VTE risk assessment and make recommendations regarding VTE prevention

4 AGENDA 9:00 am - 6:00pm CARDIOLOGY I Atrial Fibrillation/ Venous TromboEmbolism Atrial Fibrillation \ What is AF? \ Prevalence \ Impact on morbidity and mortality \ The local situation datasets \ Other important Risk factors \ Diagnosing AF Management \ The impact of AF-related stroke \ Stroke prevention strategies clinical evidence \ National and international guidelines \ Risk stratification using CHA2DS2VASc and HASBLED \ Choice of anticoagulant comparing anticoagulant options \ Optimising anticoagulation TTR, adherence \ What about aspirin in AF? \ Balancing benefit and risk - making difficult decisions \ Non-pharmacological options Management \ Rate and rhythm control \ Rate control drug choices \ Rhythm control drugs vs cardioversion vs ablation \ Monitoring anti-arrhythmic drug therapies Medicines Optimisation case studies Venous Thromboembolism \ What is VTE? \ Prevalence and Outcome \ The local situation datasets \ Diagnosing VTE Management \ VTE treatment strategies clinical evidence \ National and international guidelines \ Choice of anticoagulant comparing anticoagulant options - LMWH, VKA, NOACs \ What about aspirin in VTE? \ Initiation regimens role of heparin \ Duration of treatment \ Cancer and VTE \ Non-pharmacological options Medicines Optimisation case studies Issues With Anticoagulation Bridging for Surgery Switching agents Managing Bleeds Reversal and Antidotes Adherence

5 CONTACTS Co-Chairs Sotiris Antoniou Helen Williams Scientific Committee Sotiris Antoniou Helen Williams Fernando Fernandez-Llimos Organising Committee Andreia Duarte, HCPA Rui Rodrigues, HCPA To register or for further information, please contact the HCPA office Rua da Junqueira Nº200, 1º Andar, Lisboa Portugal Tel: Website

6 SAVE THE DATE! Places are limited for 20 PARTICIPANTS don t delay, REGISTER TODAY! Registration Fee 750 (VAT included) Fee includes lunch cofee-breaks educational material -10% (registration 2 or more sessions)

7 BREAKOUT SESSIONS DELEGATE QUOTES from previous similar HCPA Breakout Sessions: The most valuable part: the take home messages that we can apply on our work places Speakers - excellent knowledge and communication skills The program focus the most important aspects in this area Meet the people Share knowledge Learn with the best WE RE LOOKING FORWARD TO SEE YOU!